Journal List > Korean J Hematol > v.44(2) > 1032816

Lee, Jeong, Lee, Chun, Ryu, and Song: A Case of Immune Thrombocytopenic Purpura Developing after Treatment for Non-Hodgkin's Lymphoma

Abstract

Immune thrombocytopenic purpura (ITP) can be classified as primary or secondary according to the presence of an underlying non-malignant or malignant disorder, including lymphoproliferative disorders. The estimated prevalence of ITP in patients with Hodgkin's lymphoma is about 1%, and its clinical course has been reported in approximately 50 patients. ITP is an unusual and poorly documented complication in patients with non-Hodgkin's lymphoma. Some cases have been described in patients who have undergone high-dose chemotherapy and autologous bone marrow/peripheral blood stem cell transplantation. Rare cases appear to be coincidental. Here, we report on a rare case of a 61-year-old man who had ITP after being in a state of complete remission of non-Hodgkin's lymphoma for about 15 months.

References

1. Hauswirth AW, Skrabs C, Schützinger C, et al. Autoimmune thrombocytopenia in non-Hodgkin's lymphomas. Hematologica. 2008; 93:447–50.
crossref
2. Liebman H. Other immune thrombocytopenias. Semin Hematol. 2007; 44:S24–S34.
crossref
3. Kirshner JJ, Zamkoff KW, Gottlieb AJ. Idiopathic thrombocytopenia purpura and Hodgkin's disease: report of two cases and a review of the literature. Am J Med Sci. 1980; 280:21–8.
4. Cohen JR. Idiopathic thrombocytopenic purpura in Hodgkin's disease: a rare occurrence of no prognostic significance. Cancer. 1978; 41:743–6.
5. Jones SE. Autoimmune disorders and malignant lymphoma. Cancer. 1973; 31:1092–8.
crossref
6. Kaden BR, Rosse WF, Hauch TW. Immune thrombocytopenia in lymphoproliferative disease. Blood. 1979; 53:545–51.
7. Gang MS, Kim SW, Kim JS, et al. Immune thrombocytopenic purpura. Cha YJ, Goo HH, Gwon SW, editors. Hematology. 1st ed.Seoul, Korea: Epublic Press;2006. p. 497–503.
8. Hamblin TJ, Oscier DG, Young BJ. Autoimmunity in chronic lymphocytic leukaemia. J Clin Pathol. 1986; 39:713–6.
crossref
9. Váróczy L, Gergely L, Zeher M, Szegedi G, Illés A. Malignant lymphoma-associated autoimmune diseases-a descriptive epidemiological study. Rheumatol Int. 2002; 22:233–7.
10. Dührsen U, Augener W, Zwingers T, Brittinger G. Spectrum and frequency of autoimmune derangements in lymphoproliferative disorders: analysis of 637 cases and comparison with myeloproliferative diseases. Br J Haematol. 1987; 67:235–9.
crossref
11. Gr⊘nbaek K, D'Amore F, Schmidt K. Autoimmune phenomena in non-Hodgkin's lymphoma. Leuk Lymphoma. 1995; 18:311–6.
12. Diehl LF, Ketchum LH. Autoimmune disease and chronic lymphocytic leukemia: autoimmune hemolytic anemia, pure red cell aplasia, and autoimmune thrombocytopenia. Semin Oncol. 1998; 25:80–97.
13. Cooper N, Bussel J. The pathogenesis of immune thrombocytopaenic purpura. Br J Haematol. 2006; 133:364–74.
crossref

Fig. 1.
Peripheral blood shows marked thrombocytopenia (Wright-Giemsa stain, ×200).
kjh-44-113f1.tif
Fig. 2.
Computed tomography (CT) scan demonstrates multiple enlarged lymph nodes at lymphoma diagnosis (A). Follow-up CT scan shows no evidence of newly developed lesions (B).
kjh-44-113f2.tif
Fig. 3.
PET-CT scan shows no abnormal focal FDG uptake.
kjh-44-113f3.tif
Fig. 4.
Bone marrow finding showing adequate number and normal morphology of magakaryocytes. There are no aggregates or infiltrates of large lymphoid cells in the marrow space (H&E stain, ×200).
kjh-44-113f4.tif
TOOLS
Similar articles